five

Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas

收藏
NIAID Data Ecosystem2026-03-09 收录
下载链接:
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2230594
下载链接
链接失效反馈
官方服务:
资源简介:
This study evaluates the safety and performance of SGM-101, a Carcinoembryonic Antigen (CEA)-specific chimeric antibody conjugated with a NIR emitting fluorochrome, for the visualization of CEA-expressing cancers during surgery. SGM-101 is injected 2 to 4 days before surgery and visualized using an optimized camera system.
创建时间:
2016-01-15
二维码
社区交流群
二维码
科研交流群
商业服务